Lentiviral Expression

LentiBOOST® is a highly effective, non-cytotoxic transduction enhancer for preclinical and clinical application of lentiviral vectors. As universally acting (receptor independent) adjuvant it can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells and NK cells. These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies. 

The substance has become the gold standard for lentiviral transduction of HSCs. Latest results show consistently increased VCN (Vector Copy Number) per cell in the range of 3 copies per genome and high gene expression in patients 6 month after HSC therapy. This effect of an increase of vector copy numbers can also be observed for T-cells, leading to a higher transduction efficiency applying LentiBOOST®, which in return allows higher levels of expression of your therapeutic proteins.

LentiBOOST® research grade material is used for basic research only - not transferable to the clinic

LentiBOOST® pharma grade non-GMP material is used for preclinical research and process development including large scale runs

LentiBOOST® GMP material is for clinical use - Revvity Gene Delivery GmbH (formerly SIRION Biotech) holds a patent (published as WO2013127964) for this substance class and licenses the technology for clinical use. LentiBOOST® GMP material is available for process development (GMP pilot runs) under a research or clinical license. Please contact lentiboost@sirion-biotech.de

LentiBOOST-R__Manual_English_V4.1_MFB.pdf

LentiBOOST-P_Manual_English_V5.6_MFB.pdf